Gilead says Trodelvy with Merck’s Keytruda controls lung cancer Sep. 10, 2023 5:30 AM ET Gilead Sciences, Inc. (GILD) Stock, MRK Stock By: Dulan Lokuwithana, SA News Editor 11 Comments ...

(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...

Gilead Sciences, Inc. today announced promising early data from the global, open-label, Phase 2 EVOKE-02 study evaluating Trodelvy ® in combination with Merck’ s anti-PD-1 therapy KEYTRUDA ...

Gilead and Merck collaborated in 2021 to evaluate Trodelvy in combination with Keytruda in the phase III ASCENT-04/KEYNOTE-D19 study. Shares of GILD have gained 20% year to date against the ...

Gilead Sciences and Arcus are slimming down a phase 3 TIGIT trial to compare the lung cancer combo therapy to just Merck’s Keytruda, ditching a chemotherapy arm.

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with no new safety concerns.

Gilead entered into two clinical trial collaboration and supply agreements with Merck in January 2022 to evaluate the combination of Trodelvy and Merck's Keytruda in Phase 2 EVOKE-02 signal ...

Gilead's (GILD) Trodelvy with Merck's (MRK) Keytruda shows a 35% reduced risk of disease progression or death against a type of aggressive breast cancer. Read more here.

Gilead Sciences, Inc. GILD announced positive data on breast cancer drug Trodelvy (sacituzumab govitecan-hziy) from the late-stage ASCENT-04/KEYNOTE-D19 study. Data from the phase III ASCENT-04 ...

(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...